An intron, derived from the term "intragenic region", is a nucleotide sequence within a gene that does not directly code for proteins and does not remain in the final mature mRNA molecule following the gene's transcription.
A fusion protein is a protein composed of at least two domains that are encoded by separate genes fused together so that they are transcribed and translated as a single unit, producing a single polypeptide.
According to the Patsnap Bio Sequence Database, the top 10 applicants for the Vyjuvek patent are Krystal Biotech with 32 applications, Holostem Terapie Avanzate Srl with 6 applications, and FONDATION A DE ROTHSCHILD with 2 applications.
According to the Patsnap Bio Sequence Database, the top 10 applicants for the Keytruda patent are Novartis AG with 438 applications, Merck Sharp & Dohme Corp. with 350 applications, and Merck Sharp & Dohme LLC with 299 applications.
According to the Patsnap Bio Sequence Database, the top 10 applicants for the Aflibercept patent are Novartis with 80 applications, Regeneron with 60 applications, and Sanofi with 50 applications.
According to the Patsnap Bio Sequence Database, the top 10 applicants for the toripalimab patent are as follows: Shanghai Junshi Biosciences with 52 applications, Cugene with 30 applications, and Guangzhou Zhiyi Biotech with 16 applications. For more applicants, please refer to the image below.